Prospects for gene therapy in Parkinson's disease
Identifieur interne : 005592 ( Main/Exploration ); précédent : 005591; suivant : 005593Prospects for gene therapy in Parkinson's disease
Auteurs : Freese [États-Unis] ; Matthew Stern [États-Unis] ; Michael G. Kaplitt [États-Unis] ; William M. O'Connor [États-Unis] ; Maureen V. Abbey [États-Unis] ; Michael J. O'Connor [États-Unis] ; Matthew J. During [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1996-09.
English descriptors
- KwdEn :
- Adenoviridae, Corpus Striatum (physiopathology), Dopamine (biosynthesis), Gene Amplification, Gene Deletion, Gene therapy, Genes, Viral, Genetic Therapy, Genetic Vectors (therapeutic use), Herpesvirus 1, Human, Humans, Parkinson Disease (physiopathology), Parkinson Disease (therapy), Parkinson's disease, Substantia Nigra (physiopathology), Transgenes, Transplant, Viral vector, Virus Integration.
- MESH :
- chemical , biosynthesis : Dopamine.
- physiopathology : Corpus Striatum, Parkinson Disease, Substantia Nigra.
- therapeutic use : Genetic Vectors.
- therapy : Parkinson Disease.
- Adenoviridae, Gene Amplification, Gene Deletion, Genes, Viral, Genetic Therapy, Herpesvirus 1, Human, Humans, Transgenes, Virus Integration.
Abstract
Numerous advances in in vivo and ex vivo gene‐therapy approaches to Parkinson's disease offer promise for direct clinical trials in patients in the next several years. These systems are predicated on introducing genes that encode enzymes responsible for dopamine biosynthesis or neurotrophic factors that may delay nigrostriatal degeneration or facilitate regeneration. We review the current status of experimental approaches to gene therapy for Parkinson's disease. Comparative advantages and disadvantages of each system are enumerated, and preclinical trials of some of the systems are evaluated. Although the specific in vivo or ex vivo methods used for gene transfer into the brain are likely to be supplanted by newer technology over the next decade, the principles and approaches developed in current studies likely will remain the same.
Url:
DOI: 10.1002/mds.870110502
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001163
- to stream Istex, to step Curation: 001163
- to stream Istex, to step Checkpoint: 003A94
- to stream PubMed, to step Corpus: 004791
- to stream PubMed, to step Curation: 004791
- to stream PubMed, to step Checkpoint: 004775
- to stream Ncbi, to step Merge: 004B91
- to stream Ncbi, to step Curation: 004B91
- to stream Ncbi, to step Checkpoint: 004B91
- to stream Main, to step Merge: 008698
- to stream Main, to step Curation: 005592
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Prospects for gene therapy in Parkinson's disease</title><author><name sortKey="Freese" sort="Freese" uniqKey="Freese" last="Freese">Freese</name></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name></author><author><name sortKey="Kaplitt, Michael G" sort="Kaplitt, Michael G" uniqKey="Kaplitt M" first="Michael G." last="Kaplitt">Michael G. Kaplitt</name></author><author><name sortKey="O Connor, William M" sort="O Connor, William M" uniqKey="O Connor W" first="William M." last="O'Connor">William M. O'Connor</name></author><author><name sortKey="Abbey, Maureen V" sort="Abbey, Maureen V" uniqKey="Abbey M" first="Maureen V." last="Abbey">Maureen V. Abbey</name></author><author><name sortKey="O Connor, Michael J" sort="O Connor, Michael J" uniqKey="O Connor M" first="Michael J." last="O'Connor">Michael J. O'Connor</name></author><author><name sortKey="During, Matthew J" sort="During, Matthew J" uniqKey="During M" first="Matthew J." last="During">Matthew J. During</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:812CF3133052BB05C37DEF0FBC148F52DDEC4C86</idno><date when="1996" year="1996">1996</date><idno type="doi">10.1002/mds.870110502</idno><idno type="url">https://api.istex.fr/document/812CF3133052BB05C37DEF0FBC148F52DDEC4C86/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001163</idno><idno type="wicri:Area/Istex/Curation">001163</idno><idno type="wicri:Area/Istex/Checkpoint">003A94</idno><idno type="wicri:doubleKey">0885-3185:1996:Freese:prospects:for:gene</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8866488</idno><idno type="wicri:Area/PubMed/Corpus">004791</idno><idno type="wicri:Area/PubMed/Curation">004791</idno><idno type="wicri:Area/PubMed/Checkpoint">004775</idno><idno type="wicri:Area/Ncbi/Merge">004B91</idno><idno type="wicri:Area/Ncbi/Curation">004B91</idno><idno type="wicri:Area/Ncbi/Checkpoint">004B91</idno><idno type="wicri:doubleKey">0885-3185:1996:Freese A:prospects:for:gene</idno><idno type="wicri:Area/Main/Merge">008698</idno><idno type="wicri:Area/Main/Curation">005592</idno><idno type="wicri:Area/Main/Exploration">005592</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Prospects for gene therapy in Parkinson's disease</title><author><name sortKey="Freese" sort="Freese" uniqKey="Freese" last="Freese">Freese</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosurgery, University of Pennsylvania Medical Center, New Haven, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Laboratory of Molecular Neurosurgery, Graduate Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Department of Neurology, Graduate Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Kaplitt, Michael G" sort="Kaplitt, Michael G" uniqKey="Kaplitt M" first="Michael G." last="Kaplitt">Michael G. Kaplitt</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurosurgery, Cornell Medical School/New York Hospital</wicri:cityArea></affiliation></author><author><name sortKey="O Connor, William M" sort="O Connor, William M" uniqKey="O Connor W" first="William M." last="O'Connor">William M. O'Connor</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Laboratory of Molecular Neurosurgery, Graduate Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="Abbey, Maureen V" sort="Abbey, Maureen V" uniqKey="Abbey M" first="Maureen V." last="Abbey">Maureen V. Abbey</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Laboratory of Molecular Neurosurgery, Graduate Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="O Connor, Michael J" sort="O Connor, Michael J" uniqKey="O Connor M" first="Michael J." last="O'Connor">Michael J. O'Connor</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Neurosurgery, University of Pennsylvania Medical Center, New Haven, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">Pennsylvanie</region></placeName><wicri:cityArea>Division of Neurosurgery, Graduate Hospital, Philadelphia</wicri:cityArea></affiliation></author><author><name sortKey="During, Matthew J" sort="During, Matthew J" uniqKey="During M" first="Matthew J." last="During">Matthew J. During</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Section of Neurosurgery, Yale University School of Medicine, New Haven, Connecticut</wicri:regionArea><placeName><region type="state">Connecticut</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1996-09">1996-09</date><biblScope unit="vol">11</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="469">469</biblScope><biblScope unit="page" to="488">488</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">812CF3133052BB05C37DEF0FBC148F52DDEC4C86</idno><idno type="DOI">10.1002/mds.870110502</idno><idno type="ArticleID">MDS870110502</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenoviridae</term><term>Corpus Striatum (physiopathology)</term><term>Dopamine (biosynthesis)</term><term>Gene Amplification</term><term>Gene Deletion</term><term>Gene therapy</term><term>Genes, Viral</term><term>Genetic Therapy</term><term>Genetic Vectors (therapeutic use)</term><term>Herpesvirus 1, Human</term><term>Humans</term><term>Parkinson Disease (physiopathology)</term><term>Parkinson Disease (therapy)</term><term>Parkinson's disease</term><term>Substantia Nigra (physiopathology)</term><term>Transgenes</term><term>Transplant</term><term>Viral vector</term><term>Virus Integration</term></keywords><keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Corpus Striatum</term><term>Parkinson Disease</term><term>Substantia Nigra</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Genetic Vectors</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adenoviridae</term><term>Gene Amplification</term><term>Gene Deletion</term><term>Genes, Viral</term><term>Genetic Therapy</term><term>Herpesvirus 1, Human</term><term>Humans</term><term>Transgenes</term><term>Virus Integration</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Numerous advances in in vivo and ex vivo gene‐therapy approaches to Parkinson's disease offer promise for direct clinical trials in patients in the next several years. These systems are predicated on introducing genes that encode enzymes responsible for dopamine biosynthesis or neurotrophic factors that may delay nigrostriatal degeneration or facilitate regeneration. We review the current status of experimental approaches to gene therapy for Parkinson's disease. Comparative advantages and disadvantages of each system are enumerated, and preclinical trials of some of the systems are evaluated. Although the specific in vivo or ex vivo methods used for gene transfer into the brain are likely to be supplanted by newer technology over the next decade, the principles and approaches developed in current studies likely will remain the same.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Connecticut</li><li>Pennsylvanie</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="Connecticut"><name sortKey="Freese" sort="Freese" uniqKey="Freese" last="Freese">Freese</name></region><name sortKey="Abbey, Maureen V" sort="Abbey, Maureen V" uniqKey="Abbey M" first="Maureen V." last="Abbey">Maureen V. Abbey</name><name sortKey="During, Matthew J" sort="During, Matthew J" uniqKey="During M" first="Matthew J." last="During">Matthew J. During</name><name sortKey="Freese" sort="Freese" uniqKey="Freese" last="Freese">Freese</name><name sortKey="Kaplitt, Michael G" sort="Kaplitt, Michael G" uniqKey="Kaplitt M" first="Michael G." last="Kaplitt">Michael G. Kaplitt</name><name sortKey="O Connor, Michael J" sort="O Connor, Michael J" uniqKey="O Connor M" first="Michael J." last="O'Connor">Michael J. O'Connor</name><name sortKey="O Connor, Michael J" sort="O Connor, Michael J" uniqKey="O Connor M" first="Michael J." last="O'Connor">Michael J. O'Connor</name><name sortKey="O Connor, William M" sort="O Connor, William M" uniqKey="O Connor W" first="William M." last="O'Connor">William M. O'Connor</name><name sortKey="Stern, Matthew" sort="Stern, Matthew" uniqKey="Stern M" first="Matthew" last="Stern">Matthew Stern</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005592 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005592 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:812CF3133052BB05C37DEF0FBC148F52DDEC4C86
|texte= Prospects for gene therapy in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |